Faruqi & Faruqi, LLP, a prominent securities law firm with a national footprint, has launched an investigation into potential claims against Geron Corporation (NASDAQ: GERN) following recent allegations of federal securities law violations. Investors who suffered losses exceeding $100,000 between February 28, 2024, and February 25, 2025, are encouraged to contact the firm’s securities litigation partner, Josh Wilson, to discuss legal options.
The firm has set a deadline of May 12, 2025, for investors to seek the role of lead plaintiff in the ongoing federal securities class action. This role is crucial, as the lead plaintiff represents the interests of all class members, directing and overseeing the litigation process. Investors who choose not to become lead plaintiffs can still participate in any potential recovery.
The complaint against Geron Corporation alleges that the company and its executives made false and misleading statements to investors. These statements reportedly included confidence in the company’s ability to address a significant unmet need for their drug Rytelo and to execute a commercial strategy targeting first-line ESA ineligible patients. However, the company is accused of downplaying risks associated with Rytelo’s weekly monitoring requirements, the impacts of market competition, and seasonality on sales.
The situation unfolded further on February 26, 2025, when Geron announced its fourth-quarter financial results for fiscal 2024. The company disclosed that Rytelo’s growth had stalled, attributing this stagnation to seasonal factors, competitive pressures, lack of awareness, and the burdensome monitoring requirements of the drug.
Following this announcement, Geron’s stock price plummeted from a closing price of $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a significant decline of approximately 32.07% in just one day.
Faruqi & Faruqi, LLP, with offices in New York, Pennsylvania, California, and Georgia, has recovered hundreds of millions of dollars for investors since its founding in 1995. The firm encourages anyone with information regarding Geron’s conduct, including whistleblowers, former employees, shareholders, and others, to come forward.
For further information about the Geron class action lawsuit or to discuss your specific case, investors are advised to visit www.faruqilaw.com/GERN or contact Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Stay updated on developments by following fintechfilter.com.
Note: This article is inspired by content from https://www.prnewswire.com/news-releases/faruqi–faruqi-reminds-geron-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-may-12-2025—gern-302437940.html. It has been rephrased for originality. Images are credited to the original source.